Skip to main content

Market Overview

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
  • Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter.
  • Bristol-Myers holds an 11.5% stake in Acceleron. Selling the stake will bring the Merck deal closer to completion.
  • Another Acceleron investor, Avoro Capital, which holds about 7% of Acceleron’s stock, said Merck’s deal “drastically undervalues” Acceleron.
  • Related: Activist Investor Thinks Merck Undervalues Acceleron Buy.
  • Hedge fund Darwin Global, which owns 3.8% of Acceleron’s stock, urged shareholders not to tender their shares.
  • Darwin Global Management also said Acceleron execs have settled for a price that was far too low. 
  • By Darwin’s math released Wednesday, the deal undervalues Acceleron by as much as $17 billion, given the blockbuster prospects of both Reblozyl and sotatercept.
  • Another shareholder, Holocene Advisors, said last week that it didn’t plan to tender its shares.
  • Price Action: XLRN shares are up 0.67% at $173.66, BMY shares are down 0.89% at $57.56 during the market session on the last check Thursday.

Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Posted-In: Bloomberg BriefsBiotech M&A News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at